Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 12/20 | 0.44 |
| ▸ | CDK2 | P24941 | 11/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.44 |
| ▸ | CDK4 | P11802 | 6/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | CCND2 | P30279 | 3/20 | 0.39 |
| ▸ | CCND3 | P30281 | 3/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341054 | 0.84 | PIK3CA (0.47) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL8210294 | 0.80 | PIK3CA (0.55) | PIK3CA | |
| SCHEMBL29640940 | 0.79 | CCND1 (0.60) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL4220929 | 0.79 | MEN1 (0.41) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL19857389 | 0.79 | CCND1 (0.60) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL1064571 | 0.79 | CCND1 (0.37) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL3338750 | 0.79 | PIK3CA (0.58) | PIK3CA | |
| SCHEMBL5115244 | 0.78 | MEN1 (0.43) | CCND1CDK2CCNE1CDK6CDK4 | |
| SCHEMBL3339634 | 0.78 | CDK4 (0.66) | CCND1CDK2CCNE1CDK4CCND2 | |
| SCHEMBL1898968 | 0.78 | PIK3CA (0.57) | CCND1CDK2CCNE1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142543-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | CCND1 805/4885CDK2 112/4885CCNE1 758/4885 |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | CCND1 141/4885CDK2 23/4885CCNE1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.